Voyager Therapeutics has entered into a License and Collaboration Agreement with Novartis Pharma AG to provide rights to Novartis for certain proprietary adeno-associated virus (AAV) capsids for use in gene therapy products for spinal muscular atrophy and Huntington's disease, with Novartis making an upfront payment of $80 million and purchasing shares of Voyager Therapeutics.